Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors

Journal of the National Cancer Institute

Volumn 91, Issue 19, 1999, Pages 1678-1684

  Mitsiades, Nicholas ^a,b   Poulaki, Vassiliki ^a   Leone, Alvaro ^a   Tsokos, Maria ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CELL SURVIVAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; EWING SARCOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033530269     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.19.1678     Document Type: Article

References (56)

1. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995;55:1856-62.
2. Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 1997;15:175-85.
3. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75.
4. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 1995;14:1129-35.
5. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-83.
6. Tanaka M, Suda T, Haze K, Nakamura N. Sato K, Kimura F, et al. Fas ligand in human serum. Nat Med 1996;2:317-22.
7. Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, Starling GC, et al. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 1997;159:1594-8.
8. Martinez-Lorenzo MJ, Alava MA, Anel A, Pineiro A, Naval J. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology 1996;89:511-7.
9. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
10. Oehm A, Berhmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/ nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-15.
11. Brunner T, Mogil RJ, LaFaee D, Yoo NJ, Mahboubi A, Echeverri F, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995;373:441-4.
12. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
13. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265: 528-30.
14. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 1994;370:650-2.
15. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Fur J Immunol 1995;25:2253-8.
16. Hahne M, Rimoldi D, Schmier M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
17. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997;99:1173-8.
18. Sato K, Kimura F, Nakamura Y, Murakami H, Yoshida M, Tanaka M, et al. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br J Haematol 1996;94: 379-82.
19. Perzova R, Loughran TP Jr. Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Br J Haematol 1997;197: 123-6.
20. Mullauer L, Mosberger I, Chott A. Fas ligand expression in nodal non-Hodgkin's lymphoma. Mod Pathol 1998;11:369-75.
21. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184: 1075-82.
22. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med 1996;2:1361-6.
23. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 1998; 101:2579-88.
24. von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 1999;125:73-84.
25. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 1998;58:2057-62.
26. Bennett MW, O'Connell J, O'Sullivan GC, Roche D, Brady C, Kelly J, et al. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 1999;44:156-62.
27. Niehans GA, Brunner T, Frizelle SP. Liston JC, Salerno CT, Knapp DJ, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-12.
28. Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol 1998;153:1947-56.
29. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187:1205-13.
30. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998;4:31-6.
31. Sorensen PH, Wu JK, Berean KW, Lim JF, Donn W, Frierson HF, et al. Olfactory neuroblastoma is a peripheral primitive neuroectodermal tumor related to Ewing sarcoma. Proc Natl Acad Sci USA 1996;93:1038-43.
32. Bernai S, Thompson R, Gilbert F, Baylin SB. In vitro and in vivo growth characteristics of two different cell populations in an established line of human neuroblastoma. Cancer Res 1983;43:1256-60.
33. Tsokos M, Vassilopoulos D, Szentendrei T, Quezado M, Karameris A, Tsokos G. Fas-mediated apoptosis in peripheral primitive neuroectodermal tumor (PNET)/Ewing's sarcoma (ES) [abstract]. FASEB J 1996;10:A1009.
34. Slinker BK. The statistics of synergism. J Mol Cell Cardiol 1998;30:723-31.
35. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
36. Chirivi RG, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD. et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58:460-4.
37. Sledge GW Jr, Qulali M, Goulet R, Bone EA, Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995;87:1546-50.
38. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts [published erratum appears in Cancer Res 1993;53:3652]. Cancer Res 1993;53:2087-91.
39. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994;54: 4726-8.
40. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996;56:2815-22.
41. Zervos EE, Norman JG, Gower WR, Franz MG, Rosemurgy AS. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res 1997;69: 367-71.
42. Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Int J Pancreatol 1997;21:1-12.
43. Shalinsky DR, Brekken J, Zou H, Bender S, Zook S, Appell K, et al. Increased apoptosis in human androgen-independent prostatic PC-3 tumors following oral administration of a novel matrix metalloproteinase (MMP) inhibitor, AG3340, in male nude mice [abstract]. Proc Am Assoc Cancer Res 1998;39:646.
44. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373: 438-41.
45. Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S. Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-gamma and tumor necrosis factor-alpha secretion. Blood 1994;84:2622-31.
46. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 1994;54:1580-6.
47. Hedlund TE, Duke RC, Schleicher MS, Miller GJ. Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate 1998;36:92-101.
48. Mitsiades N, Kotoula V, Tsokos M, FasL induction and Fas upregulation by anticancer drugs [abstract]. Proc Am Assoc Cancer Res 1997;38:194.
49. Friesen C, Herr I, Krammer PH, Debatin KM, Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996;2:574-7.
50. Giavazzi R, Garufalo A, Ferri C, Lucchini V, Bone EA, Chiari S, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998;4:985-92.
51. Burke F, East N, Upton C, Patel K, Balkwill FR. Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. Eur J Cancer 1997;33:1114-21.
52. Griffith TS, Brunner T, Fletcher SM, Green DR. Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
53. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection [published erratum appears in Nature 1998;394:133], Nature 1995;377:630-2.
54. Runic R, Lockwood CJ, Ma Y, Dipasquale B, Guller S. Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. J Clin Endocrinol Metab 1996;81:3119-22.
55. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997; 75:69-75.
56. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998;16: 2150-6.